Home LiteratureArticle Details
PMID: 11273726 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Stage-specific differential activation of mitogen-activated protein kinases in hypertrophied and failing rat hearts.

Journal of molecular and cellular cardiology ·Vol. 33 ·No. 4 ·2001-04-00 ·Pages 733-44

Hayashida W, Kihara Y, Yasaka A, Inagaki K, Iwanaga Y, Sasayama S

Abstract

Mitogen-activated protein kinases (MAPKs) are involved in the early development of cardiac hypertrophy, but their roles in chronic left ventricular hypertrophy (LVH) are unclear. We studied the angiotensin (Ang) II-induced cardiac MAPK activation of the hypertensive Dahl salt-sensitive (DS) rats in the subacute developing LVH stage, the chronic compensated LVH stage, and the congestive heart failure (CHF) stage. In the isolated, coronary-perfused heart preparation, Ang II infusion (1x10(-6)mol/l) activated extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38-MAPK in the LV myocardium. No substantial differences were observed in the Ang II-induced ERK activation between the normotensive control DS rats and the hypertensive DS rats in either stage. In contrast, the Ang II-induced activation of JNK and p38-MAPK was augmented in the subacute LVH stage of the hypertensive DS rats, but then progressively attenuated in the chronic LVH and CHF stages. Chronic treatment with an angiotensin converting enzyme inhibitor, temocapril (20 mg/kg/day), ameliorated the responsiveness of the JNK/p38-MAPK activation, suggesting that the decreased JNK/p38-MAPK activation is a consequence of negative feedback regulation for the activated cardiac renin-angiotensin system in chronic LVH and CHF. Thus, the Ang II-induced activation of multiple cardiac MAPK pathways are differentially regulated, depending on the stages of chronic hypertrophic process. The JNK and p38-MAPK activation may be involved in the early development of adaptive LVH. However, the responsiveness of the cardiac JNK/p38-MAPK pathways progressively decreased in chronic LVH and CHF under the chronic activation of tissue renin-angiotensin system.

MeSH Terms
Angiotensin II/metabolism Angiotensin-Converting Enzyme Inhibitors/pharmacology Animals Enzyme Activation Gene Expression Heart/drug effects,physiopathology Heart Failure/enzymology,physiopathology Heart Ventricles/enzymology Hemodynamics Hypertrophy, Left Ventricular/enzymology,physiopathology In Vitro Techniques JNK Mitogen-Activated Protein Kinases Male Mitogen-Activated Protein Kinases/metabolism Myocardium/enzymology Peptidyl-Dipeptidase A/genetics RNA, Messenger Rats p38 Mitogen-Activated Protein Kinases
Chemicals
Angiotensin-Converting Enzyme Inhibitors RNA, Messenger Angiotensin II JNK Mitogen-Activated Protein Kinases Mitogen-Activated Protein Kinases p38 Mitogen-Activated Protein Kinases Peptidyl-Dipeptidase A
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Hayashida W
Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan.
Kihara Y
Yasaka A
Inagaki K
Iwanaga Y
Sasayama S
Article Info
Journal
Journal of molecular and cellular cardiology
Abbr.
J Mol Cell Cardiol
ISSN
0022-2828
Published
2001-04-00
Pages
733-44
Language
English
Region
England
NLM ID
0262322
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]